New Innovation in Digital Therapeutics Market as per Specialist with technological Innovation and worldwide Trends 2025 Propeller Health, CANARY HEALTH, Noom, Inc., 2Morrow Inc.

The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025.

North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant rate in Asia Pacific (APAC) region during the forecast period. Factors such as, increasing prevalence of the chronic diseases, acceptance of the digital health platforms, developments performed by the market players in the countries such as India, China, Australia and others are likely to propel growth of the market.

Get PDF Sample Copy Of Research Report: http://bit.ly/2EL5FFZ

Application Insights:
The digital therapeutics market by application is segmented into diabetes, cardiovascular diseases, and central nervous system diseases, respiratory diseases, smoking cessation, musculoskeletal diseases and others. In 2017, the diabetes segment held a largest market share of 26.6% of the digital therapeutics, by application. This segment is also expected to dominate the market in 2025. The growth of the market is primarily attributed to the rising prevalence of diabetes cases across the globe and also the segment is expected to grow with the fastest growth rate of 22.0% during the forecast period, 2018 to 2025.

Distribution Channel Insights:
On the basis of distribution channel, the digital therapeutics market is segmented into patients, providers, payers, and employers. In 2017, the patients segment is expected to dominate the market based on the distribution channel contributing a share of 39.2%. This is primarily attributed to growing prevalence for the need to self-monitor as well as manage one’s health status. However, providers segment is anticipated to grow at a fastest growth rate of 21.3% during the forecast period.

Rising prevalence of chronic diseases to boost market growth:
Chronic diseases, including heart disease, stroke, diabetes, and obesity, are the leading causes of death in the world and account for most of the nation’s health care costs. According to report of CDC, in 2018, approximately more than 9% of the population has diabetes, which is the leading cause of kidney failure, lower-limb amputations in US. Moreover, the data also suggests that 1.5 million Americans are diagnosed with diabetes every year in the US. Similar trends for high presence of diabetes are prevalent around other geographies of the globe that include Asia Pacific, Europe, Middle East and Africa. For instance, according to IDF Diabetes Atlas published by the International Diabetes Federation in 2017, south-east Asia is home to approximately one-fifth (19%) of the total diabetes population worldwide. According to the report of American College of Cardiology Foundation, in 2018, Coronary heart disease (CHD) was the leading cause of deaths attributable to cardiovascular disease (CVD) in the US, which is followed by stroke (16.8%), high BP (9.4%), heart failure (HF) (9.0%), and other CVDs (17.9%). By 2035, approximately 130 million adults in the US population are projected to have some form of CVD. Thus, increasing geriatric population and related chronic diseases are expected to propel the growth of global digital therapeutics market over the forecast years.

Rising Pressure on Healthcare Providers to Reduce Healthcare Costs:
Digital therapeutics help in reducing the costs associated with chronic diseases, by helping an individual or an insurance provider to keep a track of one’s health status as well as track it with the help of digital means. As per American Diabetes Association, the estimated costs of diagnosed diabetes have risen to $327 billion in 2017, including $237 billion in direct medical costs and $90 billion in reduced productivity. This cost can be managed efficiently by including digital therapeutics that are offered by providers to help manage diabetes, can help patients get assistance with disease management and overcome the logistical challenges uncovered by the investigators.

GET DISCOUNT ON THIS REPORT@ http://bit.ly/2Hf3dZQ

Strategic Insights
Product launch/update and partnerships were observed as the most adopted strategy in global digital therapeutics industry. Few of the product approvals and partnerships made by the players in the market are listed below:

2017: In November, Propeller Health and Express Scripts entered into a partnership to provide Propeller’s FDA-cleared digital solutions to Express Scripts to manage asthma or COPD.

2016: In November, Propeller Health received FDA approval for its Propeller platform for use with GSK’s Ellipta inhaler.

2018: In April, Canary Health entered into a partnership with NMRHCA to offer the Better Choices, Better Health (BCBH) digital therapeutics program in New Mexico.

2016: In June, Canary Health partnered with Medtronic to expand their diabetes care offerings with Canary Health's self-management suite for pre-diabetes, diabetes and related comorbidities.

About Us
The Insight Partners Is A One Stop Industry Research Provider Of Actionable Intelligence. We Help Our Clients In Getting Solutions To Their Research Requirements Through Our Syndicated And Consulting Research Services.
We Are Committed To Providing Highest Quality Research And Consulting Services To Our Customers. We Help Our Clients Understand Key Market Trends, Identify Opportunities, And Make Informed Decisions By Providing Market Research Solutions At An Affordable Cost.

The insight partners,
Call: +1-646-491-9876
email: sales@theinsightpartners.com
Website: http://www.theinsightpartners.com/

This release was published on openPR.